Rocket Pharmaceuticals’ RP-A601 receives FDA designations
09 Jun 2023
Fast TrackOrphan DrugPhase 1Gene TherapyCell Therapy
Preview
Source: Pharmaceutical Technology
RP-A601 is designed to treat plakophilin-2-related arrhythmogenic cardiomyopathy (PKP2-ACM). Credit: Africa Studio via Shutterstock.com.
Preview
Source: Pharmaceutical Technology
Rocket Pharmaceuticals has received fast track and orphan drug designations for RP-A601 from the US Food and Drug Administration (FDA) to treat plakophilin-2-related arrhythmogenic cardiomyopathy (PKP2-ACM).
RP-A601 is an adeno-associated virus-based gene therapy currently being evaluated as a one-time, potentially curative treatment to improve survival and quality of life for PKP2-ACM patients.
The existing standard of care for the disease includes medical therapy, ablation procedures and implantable cardioverter defibrillators (ICDs).
An estimated 50,000 people in Europe and the US are affected by PKP2-ACM.
Rocket Pharmaceuticals stated that the fast-track designation enables increased communication with the regulator across the development cycle of the gene therapy.
Fast-track status also offers the potential for expedited approval of RP-A601 and permits a rolling review of the biologic licence application.
In April 2023, the FDA approved the investigational new drug (IND) application for RP-A601 to begin a Phase I clinical trial.
The dose escalation, multi-centre trial is designed to assess the preliminary efficacy and safety of RP-A601 in a minimum of six adult PKP2-ACM patients with ICDs and who are at high risk for arrhythmias.
The impact of RP-A601 on PKP2 myocardial protein expression, clinical predictors of life-threatening ventricular arrhythmias, cardiac biomarkers and sudden cardiac death will be studied in the trial.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.